We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 90

Health Canada finalizes Risk Assessment Framework for the Consumer Product Safety Program
  • Stikeman Elliott LLP
  • Canada
  • March 24 2015

As previously reported at the consultation stage, Health Canada has completed its process of developing a Risk Assessment Framework (the Framework


Federal Court opines on precedential value of prior PM(NOC) proceedings and scope of experimental use exception to public disclosure
  • Stikeman Elliott LLP
  • Canada
  • November 24 2016

The Federal Court’s decision inthe consolidated proceedings of Bayer Inc. v Cobalt Pharmaceuticals Company offers useful guidance as to the


B.C. Court dismisses proposed class action against generic manufacturers of fentanyl patch
  • Stikeman Elliott LLP
  • Canada
  • July 8 2014

On June 20, 2014, Justice Bracken of the British Columbia Supreme Court dismissed a proposed class action against two generic manufacturers of


Health and environmental claims an ongoing bureau focus
  • Stikeman Elliott LLP
  • Canada
  • December 18 2007

Investigations and enforcement actions over marketing and advertising claims related to health products and services have been a significant part of the Bureau's recent fair-business-practices work


CSA report on medical marijuana issuer finds disappointing disclosure deficiencies
  • Stikeman Elliott LLP
  • Canada
  • February 23 2015

The Canadian Securities Administrators today released the results of CSA staff's review of continuous disclosure by reporting issuers announcing


British Columbia Court of Appeal overturns certification of pharmaceutical class action
  • Stikeman Elliott LLP
  • Canada
  • February 20 2015

In a decision released January 22, 2015, the B.C. Court of Appeal unanimously overturned an order certifying a class proceeding against the


Senate Committee releases final report on Prescription Pharmaceuticals in Canada
  • Stikeman Elliott LLP
  • Canada
  • March 30 2015

On March 10, 2015, the Standing Senate Committee on Social Affairs, Science and Technology (the Committee) released a final report entitled


Snoops and gossips beware: Ontario Government to introduce stiffer measures to protect patient privacy
  • Stikeman Elliott LLP
  • Canada
  • June 26 2015

Recently, the Government of Ontario announced its intent to strengthen the rules protecting patient privacy. If passed, these amendments to the


Proposed amendments to the Food and Drugs Act impose stricter after-market regulation on drugs and medical devices
  • Stikeman Elliott LLP
  • Canada
  • May 20 2014

The Minister of Health has introduced Bill C-17 An Act to Amend the Food and Drugs Act in the House of Commons, which is currently at the second


Competition Bureau questions: Why don't we see more health care advertising?
  • Stikeman Elliott LLP
  • Canada
  • October 14 2016

Due to regulations by provincial governments and self-regulating professional bodies, Canadian health care professionals face significant